Eyepoint's Vision Treatment Trial Falls Short, Stock Takes a Hit

Eyepoint announced on Monday that its experimental treatment for age-related blindness did not deliver the expected results in a recent Phase 3 trial, as patients struggled to maintain vision with fewer injections compared to standard treatments.

This disappointing outcome jeopardizes Eyepoint's plans for regulatory approval of Duravyu and sent its stock tumbling, while shares of competitor Ocular Therapeutix rose in response.

Source: www.statnews.com